REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

Similar documents
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

Drug Treatment Program Update

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

HIV Drugs and the HIV Lifecycle

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

HIV medications HIV medication and schedule plan

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary


Antiretroviral Dosing in Renal Impairment

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

ANTIRETROVIRAL TREATMENTS (Part 1of

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Section H: Treatments

Nothing to disclose.

Nobel /03/28. HIV virus and infected CD4+ T cells

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

104 MMWR December 17, 2004

Industry Data Request

AIDS Drug Assistance Program ADAP-Miami. NEEDS ASSESSMENT July 16, 2010

Antiretrovial Crushable/Liquid Formulation Chart

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Human Immunodeficiency Virus Infection A Modern Day Epidemic

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Addressing Pediatric Needs of the Most Neglected: next steps

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

Industry Request Integrase Inhibitors

HIV Infection & AIDS in Low- and Middle-Income Countries

Appropriate Use & Safety Edits

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

Division of Public Health Services Office of the Assistant Director Public Health Preparedness Services

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

HIV for the Non-ID Pharmacist

Genotyping and Drug Resistance in Clinical Practice. Case Studies

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

Comprehensive Guideline Summary

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

HIV / AIDS & Opportunistic Infections.

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

HIV Management Update 2015

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

HIV/AIDS Update 2007

treatment passport 1

October 26-28: Training Day 1

Antiretroviral Pregnancy Registry

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

Simplifying HIV Treatment Now and in the Future

Approach for the Newly Diagnosed HIV Positive Patient

New Frontiers for Treatment Strategies for HIV Care

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

Continuing Education for Pharmacy Technicians

continuing education for pharmacists

HIV and AIDS An update

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Principles of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

TRANSPARENCY COMMITTEE

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

Central Nervous System Penetration of ARVs: Does it Matter?

Medication Errors Focus on the HIV-Infected Patient

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

Selecting an Initial Antiretroviral Therapy (ART) Regimen

NATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project

The Hospitalized HIV+ Patient

Human Immunodeficiency Virus (HIV)

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents

Pediatric Antiretroviral Resistance Challenges

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

30 Years of HIV: An Update on Treatment Guidelines and Beyond

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

Overview of HIV. LTC Paige Waterman

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

Year 2002 Paper two: Questions supplied by Jo 1

HIV epidemiology since HIV in the United States. HIV Transmission

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

Transcription:

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir, 3TC, d4t, ddi EC, tenofovir NRTIs (combination): AZT/3TC (Combivir ), AZT, 3TC, abacavir (Trizivir ), abacavir/3tc (Kivexa ), tenofovir/ftc (Truvada ), emtricitabine/tenof ovir/ efavirenz (Atripla ) NNRTIs: delavirdine, efavirenz, etravirine, nevirapine PIs: Darunavir, fosamprenavir, indinavir, lopinavir/ritonavir nelfinavir, ritonavir, saquinavir Antivirals Acyclovir Ganciclovir IV, Famciclovir, Valacyclovir, Integrase Inhibitors: raltegravir PIs: tipranavir (Aptivus ) Entry inhibitors: enfuvirtide, maraviroc Didanosine pediatric powder (SAP), d4t oral liquid (SAP) Foscarnet, Cidofovir (SAP)

Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Acyclovir 800 mg tablets and IV, Valganciclovir Antifungals Clotrimazole vag tabs, Nystatin, Ketoconazole, IV Ampho B Itraconazole capsules and solution Fluconazole Liposomal amphotericin (Ambisome), voriconazole Ampho B lozenges, Ampho B oral solution, Clotrimazole troches, Flucytosine (SAP) PCP/Toxo Agents TMP/SMX, TMP, Clindamycin, Folinic Acid, Dapsone Atovaquone liquid, Pyrimethamine Primaquine Aerosolized Pentamidine, Sulfadiazine, Trimetrexate (SAP) Mycobacterials Isoniazid, Rifampin, Pyrazinamide, Ethambutol, B 6, Clarithromycin tabs and liquid, Azithromycin 250 mg tabs or liquid Azithromycin 600 mg tablets Rifabutin, Ciprofloxacin Amikacin Clofazimine, streptomycin (SAP); INH, RIF, ETM, PZA, B 6 (CDCNU); 2nd line TB drugs (Toronto Public Health) Misc. Megace, nabilone, most NSAIDs, codeine, morphine, hydromorphone, oxycodone + AAS or acetaminophen Doxycycline, paramomycin, nutritional products, pneumococcal vaccine, potassium supplements Fentanyl patch, gabapentin, ondansetron, pancreatic enzyme (Cotazyme ECS 20), interferon α-2a, interferon α-2b, diphenoxylate / atropine, loperamide, dronabinol, oxycodone, testosterone patch (Androderm), testosterone gel (Androgel) Ketorolac, G-CSF (Neupogen), octreotide, somatropin (Serostim), imiquimod (Aldara) Albendazole, aldesleukin, GM-CSF, Thalidomide (SAP); oxandrolone (SAP - but need to pay in advance: call (613) 957-1063); Altiretinoin (Panretin ) - SAP Prepared by: Alice Tseng, Pharm.D., FCSHP, Toronto General Hospital January 2009

OBTAINING ANTIRETROVIRALS IN ONTARIO Drug Status Patient Criteria MD Criteria Paperwork/Pharmacy Cost/Month Combination products: AZT 300 mg/3tc 150 mg tablets (Combivir ) AZT 300 mg/ 3TC 150 mg/abacavir 300 mg tablets (Trizivir ) abacavir 600 mg/ 3TC 300 mg tablets (Kivexa ) Emtricitabine 200 mg/ tenofovir 300 mg tablets (Truvada ) Emtricitabine 200 mg/ tenofovir 300 mg/ efavirenz 600 mg tablets (Atripla ) /Trillium plan /Trillium plan /Trillium plan /Trillium plan /Trillium plan Nucleoside Reverse Transcriptase Inhibitors: abacavir (Ziagen ) /Trillium plan AZT, zidovudine 100 mg capsules (Retrovir ) Ont. Drug Distribution/ Ontario Health Card CD 4 <500 MD on List MD on List MD on List MD on List MD on List MD on List Antiretroviral Registration Form to Ont. Drug Distribution/ follow-up info q3months Pick up Rx at designated hospital pharmacy $626.47 $1038.61 $683.84 $751.50 $1173.25 $412.16 $314.26

Drug Status Patient Criteria MD Criteria Paperwork/Pharmacy Cost/Month ddi pediatric oral solution (Videx ) Ont. Drug Distribution/, Ontario Health Card CD 4 <200 Antiretroviral Registration Form to Ont. Drug Distribution/ ; follow-up info q3months Pick up Rx at designated hospital pharmacy ddi + cost of Maalox + 10.49 disp. Fee Individual Clinical Review (ICR) application (incl. cost of Maalox & extemporaneous compounding) made to Director of Drug s Branch, fax ddi enteric coated tablets 3TC, lamivudine d4t, stavudine (Zerit ) tenofovir (Viread ) Integrase Inhibitor: raltegravir (Isentress ) /Trillium plan /Trillium plan /Trillium plan /Trillium plan Non-Nucleoside Reverse Transcriptase Inhibitors: Delavirdine (Rescriptor ) /Trillium plan efavirenz (Sustiva ) etravirine (Intelence ) MD on List MD on List MD on List MD on List (416) 327-7526 /Trillium plan Individual Clinical Review (ICR) s Branch, fax (416) 327-7526 /Trillium plan /Trillium plan MD on List MD on List MD on List $324.90 $290.15 $277.83 $502.13 $810.00 $258.41 $421.75 $654.00

Drug Status Patient Criteria MD Criteria Paperwork/Pharmacy Cost/Month nevirapine /Trillium plan MD on $296.30 (Viramune ) List Protease Inhibitors: atazanavir (Reyataz ) darunavir (Prezista ) fosamprenavir (Telzir ) indinavir (Crixivan ) lopinavir/ ritonavir (Kaletra ) nelfinavir (Viracept ) ritonavir liquid or capsules (Norvir ) Saquinavir 500 mg tablet (Invirase ) Tipranavir (Aptivus ) /Trillium plan /Trillium plan /Trillium plan /Trillium plan /Trillium plan /Trillium plan /Trillium plan /Trillium plan MD on List MD on List MD on List MD on List MD on List MD on List MD on List MD on List /Trillium plan Individual Clinical Review (ICR) s Branch, fax (416) 327-7526 $624.06; $665.33 $644.40-947.09 $950.40; $562.01 $484.80; $410.00 $648.05 $546.00 $43.40-173.62 (booster doses) $590.81 $1262.62

Drug Status Patient Criteria MD Criteria Paperwork/Pharmacy Cost/Month Fusion Inhibitors Enfuvirtide (Fuzeon ) /Trillium plan 6 months therapy with each ARV class and documented resistance mutations to 2 drugs in each class virologic failure (RNA>50 copies/ml after 6 months and <1 log drop after 12 weeks on most recent regimen) use in combination with 1 other sensitive ARV Individual Clinical Review (ICR) s Branch, fax (416) 327-7526 $2385.60 CCR5 Inhibitor: maraviroc (Selzentry ) /Trillium plan Individual Clinical Review (ICR) s Branch, fax (416) 327-7526 $990.00 Alice Tseng, ACPR, Pharm.D.,FSCHP, Toronto General Hospital, Toronto, ON Updated June 18, 2009